BioInvent International

Business and Financial Review • Dec 17, 2015

PRESS RELEASE 17 December 2015

BioInvent selected for manufacturing services by global pharmaceutical company; expects to generate about SEK 25 million in revenue

Lund, Sweden – 17 December 2015, – BioInvent International (OMXS: BINV) today announces that the company has been selected by a major global pharmaceutical company to provide manufacturing services for one of the products in the pharmaceutical company's development portfolio.

"Being selected by this global customer to provide manufacturing services speaks to our leading expertise when it comes to antibodies. Our cGMP-certified production facilities meet EU standards for the production of antibodies, ranging from use in research all the way to phase III clinical trials," said Michael Oredsson, President and CEO of BioInvent. 'The agreement is expected to generate about SEK 25 million in revenue over the next three quarters, with the possibility for additional activities as the project progresses', Mr. Oredsson concluded.

Terms and the pharmaceutical company were not disclosed, but the agreement includes payments for manufacturing and providing services such as quality assurance.

To the editors:

About BioInvent

BioInvent International AB develops immune oncology drugs. With one of the world's largest antibody libraries, and a unique, proprietary discovery method, BioInvent can identify the optimal cellular targets and antibodies for the treatment of various tumor types. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. This makes it possible to develop proprietary drug projects, but also to supply leading international pharmaceutical companies with effective tools for their drug development. BioInvent currently has three proprietary projects in or close to clinical development and partnership agreements with seven global pharmaceutical and biotech companies. More information is available at www.bioinvent.com.

For further information, please contact:

Michael Oredsson President and CEO +46 (0)46 286 85 67 +46 (0)707 16 89 30 michael.oredsson@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263 Visiting address: Sölvegatan 41 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 info@bioinvent.com www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 17 December, 2015.